Major Price Cuts for Cancer Drugs: 137 Medications to See Up to 70% Reduction

New Delhi, October 17 (Daily Kiran) : The Indian government has announced a significant relief for cancer patients by reducing the prices of 137 non-scheduled anti-cancer medications. This decision comes from the National Pharmaceutical Pricing Authority (NPPA), which operates under the Ministry of Chemicals and Fertilizers. The new pricing strategy, known as Trade Margin Rationalization (TMR), is expected to lower the maximum retail prices (MRP) of these drugs by up to 70%.

These revised prices will take effect on November 9, 2026. This initiative builds on the success of a pilot TMR program from 2019, which limited the trade margin on 42 anti-cancer drugs to 30%. Following that pilot, the MRP of 526 brands of non-scheduled anti-cancer medications was reduced by as much as 90%. The current expansion of this approach is based on recommendations from a committee of cancer specialists and medical experts working under the Directorate General of Health Services (DGHS).

The expert committee reviewed 137 medications for inclusion under the TMR framework, and this list will be updated periodically. In line with the recommendations, the NPPA has capped the trade margin at 30% of the MRP, as per Article 19 of the Drug Price Control Order (DPCO), 2013. The official notification regarding this decision was published on October 17, 2026, and is available on the NPPA’s website.

This measure is expected to provide substantial relief to many patients and their families who often face significant financial burdens due to high treatment costs. Manufacturers are required to inform the NPPA of their revised prices within seven days of the notification. From November 9, 2026, they must display the updated price lists on their websites and distribute them widely to retailers and hospitals. Retailers and hospitals will also be required to sell the drugs at the new lower prices and display these revised rates in their pharmacies.

Given that a significant supply of anti-cancer medications is distributed directly to hospitals and medical institutions, these entities will be responsible for ensuring compliance with the new pricing from the implementation date. State drug controllers will take necessary steps to ensure that manufacturers, retailers, hospitals, and medical institutions comply with the new regulations.

The TMR initiative aims to control excessive trade margins in distribution and retail channels, protect legitimate revenue for manufacturers, and prevent artificial shortages in the market. Pharmaceutical companies must maintain current production and supply levels for the notified formulations to ensure patients receive their medications promptly and without interruption.

By making anti-cancer drugs more affordable and accessible, this initiative will help reduce the financial burden on patients and their families, supporting the broader public health goal of equitable access to cancer treatment.